The clinically applied PARP inhibitor talazoparib ameliorates imiquimod-induced psoriasis in mice without reducing skin inflammation

The clinically applied PARP inhibitor talazoparib ameliorates imiquimod-induced psoriasis in mice without reducing skin inflammation

BackgroundConsidering the role PARPs play in inflammation, we assessed the effect of PARP inhibition in an inflammatory skin condition, psoriasis, to explore novel avenues for the potential repurposing of PARP inhibitors that are currently used in tumour therapy.MethodsThe imiquimod (IMQ)-induced mo...

Full description

Saved in:
Bibliographic Details
Main Authors: Petra Molnár, Máté Ágoston Demény, Beáta Várkonyi, Zsuzsanna Polgár, Ágnes Pór, Ilona Kovács, Andrea Szegedi, Attila Gábor Szöllősi, Magdolna Szántó
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-02-01
Series:Frontiers in Pharmacology
Subjects:
PARP inhibitor
psoriasis
terminal differentiation
apoptosis
mitochondria
drug repurposing
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1519066/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2025.1519066/full

Similar Items